SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 13, 2003
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
000-23265 | 94-3267443 | |
(Commission file Number) | (IRS Employer ID Number) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
Item 5. Other Events and Regulation FD Disclosure
On October 13, 2003, Salix Pharmaceuticals, Ltd. (the “Registrant”) issued a press release announcing results of an open label study suggesting that Rifaximin, a non-systemic, gastrointestinal site-specific antibiotic, was well tolerated and may be effective for the treatment of active Crohn’s disease. A copy of this press release is attached as an exhibit hereto.
Item 7. Financial Statements and Exhibits.
(c) | Exhibits |
Exhibit No. | Description | |
99.1 | Press release dated October 13, 2003, announcing results of an open label study suggesting that Rifaximin, a non-systemic, gastrointestinal site-specific antibiotic, was well tolerated and may be effective for the treatment of active Crohn’s disease. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 13, 2003 | SALIX PHARMACEUTICALS, LTD.
By: /s/ Adam C. Derbyshire Adam C. Derbyshire Senior Vice President and Chief Financial Officer |